Dr. Reddy's Laboratories announced the
launch of Bupropion Hydrochloride Extended-Release Tablets, USP (SR), a therapeutically equivalent generic
version of Zyban (Bupropion Hydrochloride) Extended-Release Tablets, approved by the U.S. Food and Drug
Administration (USFDA).
The Zyban brand and generic had U.S. sales of approximately $5.4 million MAT for the most recent twelve months ending in June 2019 according to IQVIA Health.
Dr. Reddy's Bupropion Hydrochloride Extended-Release Tablets, USP (SR) are available as 150 mg dosage strength in bottle count sizes of 60.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
